Vibegron fda approval?

What did the FDA approve for vibegron?

Vibegron (brand name Gemtesa) is an oral medication approved by the FDA to treat symptoms of overactive bladder, including urgency and frequency. [1]

When did vibegron get FDA approval?

The FDA approved vibegron on September 21, 2020. [1]

Who makes vibegron (Gemtesa)?

Gemtesa is marketed by Myrbetriq maker? (Not provided in the supplied sources). The FDA’s approval information identifies the product as Gemtesa, but the provided source does not include the manufacturer name. [1]

What does this mean for patients and prescribers?

With FDA approval, clinicians can prescribe vibegron for adults with overactive bladder to help reduce bladder urgency and the number of times a patient urinates. [1]

Are there patent or exclusivity timelines to watch?

For current patent/exclusivity tracking for vibegron, see DrugPatentWatch.com’s page for the drug. [2]

Sources

1. https://www.drugs.com/history/vibegron.html
   
2. https://www.drugpatentwatch.com/p/vibegron